Cell and gene therapies are comprised of multiple elements including living cells or viral vectors and therefore pose additional bioanalytical challenges compared with chemical or biological drugs. The capability of bioanalytical methods to monitor cell and gene therapy safety and efficacy plays a significant role in the therapy’s success. In this six-part series, we are joined by industry experts exploring topics from regulatory implications to immunogenicity testing, delving into every corner of the cell and gene therapy landscape in bioanalysis.

    Be the first to hear about the next episode by signing up for email notifications!

The new frontier: regulatory implications for cell and gene therapies

In the first episode of The new frontier podcast, we spoke to Executive Director and Global Head of Regulatory Services Kimberley Buytaert-Hoefen about her experience with cell and gene ...

Read more

The new frontier: immunogenicity testing for cell and gene therapies

In the second episode of ‘The new frontier’, we spoke to Senior Director Johanna Mora about her experience with immunogenicity testing for cell and gene therapies (CGTs) and ...

Read more

The new frontier: using LC–MS/MS for quantitative assays to support gene therapies

In the third episode of The New Frontier podcast, we’re joined by Daniel Schulz-Jander, Senior Director of Mass spectrometry Bioanalysis at QPS Netherlands (Groningen). Daniel ...

Read more

The new frontier: ddPCR for cell therapies

In the fourth episode of The New Frontier podcast, we’re joined by Sebastian Guelman, Senior Principal Scientist for Bioanalytical Sciences from Genentech (CA, USA). Sebastian ...

Read more

The new frontier: qPCR vs ddPCR for cell and gene therapies

In the fifth episode of The new frontier podcast, we’re joined by Paul Byrne, Senior Director of Genomics from ProtaGene (MA, USA). Paul describes his experience working with qPCR ...

Read more

Sponsor